Search clinical trials for: Bortezomib administration

Total 4174 results

Indiana University

Completed

A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients

Hematopoetic Stem Cell Transplant

United States
Gustave Roussy, Cancer Campus, Grand Paris

Terminated

A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer

STAGE IIIB OR IV NON-SMALL CELL LUNG CANCER

France
Vivatech

Completed

Investigation of Kritech Efficacy on Subjects Having Functional Discomfort Associated to Joints and Muscles Disorders (Easykrill)

Pain

France
University Hospital, Toulouse
Dana-Farber Cancer Institute; Celgene Corporation; Janssen-Cilag Ltd.

Completed

Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years (IFM/DFCI2009)

Myeloma

France
University Medical Center Groningen
Erasmus Medical Center

Completed

Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging (TARGET)

Papillary Thyroid Cancer | Lymph Node Metastases

Netherlands
The First Affiliated Hospital of Soochow University

Unknown

Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China (MM)

Multiple Myeloma Proved by Laboratory Tests

China
Baylor College of Medicine
Millennium Pharmaceuticals, Inc.

Completed

PS-341 Followed by Removal of Prostate for Those With Prostate Cancer

Prostate Neoplasms

United States
NCIC Clinical Trials Group

Completed

Bortezomib in Treating Patients With Mantle Cell Lymphoma

Lymphoma

Canada
University Hospital, Clermont-Ferrand
Laboratoires Takeda

Unknown

Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple (SENSIB)

Multiple Myeloma | Adult | Bortezomib Regimen

France
Janssen-Cilag International NV

Completed

Velcade Consolidation Bone Study

Multiple Myeloma

Turkey, Greece, Czech Republic, Austria, Germany, Sweden, United Kingdom, Denmark
University Health Network, Toronto
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter

United States, Canada
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

Lung Cancer

Canada, United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

PS-341 in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy

Lymphoma

United States
NYU Langone Health
National Cancer Institute (NCI)

Completed

PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma

Lymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

United States
Nordic Myeloma Study Group
Janssen-Cilag Ltd.

Completed

Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients

Multiple Myeloma

Norway, Sweden, Denmark, Finland, Iceland
Nantes University Hospital

Completed

Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma

Multiple Myeloma

France
Millennium Pharmaceuticals, Inc.

Completed

Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability

Multiple Myeloma

United States
Jonsson Comprehensive Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Jonsson Comprehensive Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Bortezomib in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States
University of Rochester

Completed

Bortezomib in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Janssen Korea, Ltd., Korea

Completed

Quality of Life in Multiple Myeloma Patients Treated With Bortezomib

Multiple Myeloma
NCIC Clinical Trials Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group

Completed

Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

Canada, United States
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors

Islet Cell Tumor | Gastrointestinal Carcinoid Tumor

United States
Northwestern University
National Cancer Institute (NCI)

Completed

PS-341 in Treating Women With Metastatic Breast Cancer

Breast Cancer

United States
Janssen Pharmaceutical K.K.

Completed

An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy

Multiple Myeloma
Janssen Pharmaceutical K.K.

Completed

A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients

Multiple Myeloma | Relapse | Refractory
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

PS-341 in Treating Patients With Metastatic Kidney Cancer

Kidney Cancer

United States
Chinese SLE Treatment And Research Group

Recruiting

Bortezomib for the Treatment of Refractory Rheumatoid Arthritis

Rheumatoid Arthritis

China
Weill Medical College of Cornell University
GlaxoSmithKline; Millennium Pharmaceuticals, Inc.

Completed

Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy

Non-Hodgkin's Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder

Gastrointestinal Cancer | Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder... and other conditions

United States
International Extranodal Lymphoma Study Group (IELSG)

Terminated

VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy

Lymphoma, Mucosa-Associated Lymphoid Tissue

Switzerland
Janssen Korea, Ltd., Korea

Completed

Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients.

Multiple Myeloma
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma

Sarcoma

United States
University of Wuerzburg

Unknown

VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)

Multiple Myeloma

Austria, Germany, Italy
Sidney Kimmel Cancer Center at Thomas Jefferson...
Millennium Pharmaceuticals, Inc.

Completed

A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients

Head and Neck Cancer | Central Nervous System Neoplasms | Brain Cancer | Cervix Cancer

United States
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Millennium...

Completed

Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia

Lymphoplasmacytic Lymphoma | Waldenstrom's Macroglobulinemia

United States
Vejle Hospital
Odense University Hospital

Completed

The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer)

Multiple Myeloma

Denmark
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer

Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer

United States
Janssen-Cilag B.V.

Completed

VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands

Multiple Myeloma | Hematological Neoplasms

Netherlands
Mayo Clinic
National Cancer Institute (NCI)

Completed

PS-341 in Treating Patients With Advanced Cancer

Lymphoma | Leukemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant

Multiple Myeloma and Plasma Cell Neoplasm

United States
Zhongnan Hospital

Recruiting

Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML

Acute Myeloid Leukemia | Bortezomib

China
BiondVax Pharmaceuticals ltd.

Completed

A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers

Healthy | Influenza

Israel
Genentech, Inc.
Seagen Inc.

Completed

A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.

Active, not recruiting

Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Janssen-Cilag International NV

Completed

Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma

Multiple Myeloma
Jonsson Comprehensive Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Bortezomib in Treating Patients With Metastatic Kidney Cancer

Kidney Cancer

United States

Search clinical trials for: Bortezomib administration

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations